<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: We sought to identify genes of clinical significance to predict survival and the risk for colorectal <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e> (CLM), the most common site of <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> from <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>PATIENTS AND METHODS: We profiled gene expression in 31 specimens from primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> and 32 unmatched specimens of CLM, and performed Significance Analysis of Microarrays (<z:chebi fb="75" ids="15414">SAM</z:chebi>) to identify genes differentially expressed between these two groups </plain></SENT>
<SENT sid="2" pm="."><plain>To characterize the clinical relevance of two highly-ranked differentially-expressed genes, we analyzed the expression of secreted phosphoprotein 1 (SPP1 or osteopontin) and lymphoid enhancer factor-1 (LEF1) by immunohistochemistry using a tissue microarray (<z:chebi fb="39" ids="18139,53050">TMA</z:chebi>) representing an independent set of 154 patients with primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Supervised analysis using <z:chebi fb="75" ids="15414">SAM</z:chebi> identified 963 genes with significantly higher expression in CLM compared to primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>, with a false discovery rate of &lt;0.5% </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="39" ids="18139,53050">TMA</z:chebi> analysis showed SPP1 and LEF1 protein overexpression in 60% and 44% of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cases, respectively </plain></SENT>
<SENT sid="5" pm="."><plain>Subsequent occurrence of CLM was significantly correlated with the overexpression of LEF1 (chi-square p = 0.042), but not SPP1 (p = 0.14) </plain></SENT>
<SENT sid="6" pm="."><plain>Kaplan Meier analysis revealed significantly worse survival in patients with overexpression of LEF1 (p&lt;0.01), but not SPP1 (p = 0.11) </plain></SENT>
<SENT sid="7" pm="."><plain>Both univariate and multivariate analyses identified stage (p&lt;0.0001) and LEF1 overexpression (p&lt;0.05) as important prognostic markers, but not <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> grade or SPP1 </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION: Among genes differentially expressed between CLM and primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>, we demonstrate overexpression of LEF1 in primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> to be a prognostic factor for poor survival and increased risk for <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e> </plain></SENT>
</text></document>